Fractyl Health, Inc

Fractyl Health’s mission is to cure metabolic diseases by addressing their root cause: insulin resistance. The company has developed an innovative minimally invasive outpatient approach to treat insulin resistance with a medical device. The device is designed to rejuvenate the lining of the duodenum which leads to a significant decrease in insulin resistance. Currently, the device targets patients with type 2 diabetes, polycystic ovarian syndrome (PCOS) and nonalcoholic steatohepatitis (NASH).

Fractyl’s device is a treatment of the underlying disease and not just its symptoms. Clinical trials are being held in various locations around the world, with promising results, and commercialization has started in Europe.

Industry: Medical Devices Headquarters: USA Year Invested: 2017 Visit Website